AskBorsa

Minapharm Pharmaceuticals

MIPH
Fiscal year starts in January · currency EGP · latest: Q2 2026
Next results: Q3 2026 — expected around 15 November 2026published last year on 13 November 2025Results calendar ←
754.00EGP+1.45% today1w −0.5%1m −8.0%delayed · 3 November
Net profit · 2024
157million
▲ 591.0% vs 2023
Total assets · 2024
12billion
▲ 37.9% vs 2023
Shareholders' equity · 2024
4.41billion
▲ 25.4% vs 2023
Operating cash flow · 2024
222million
▲ 109.6% vs 2023

Key facts

Source: annual statements 2024
  • Minapharm Pharmaceuticals's net profit in 2024 was 157 million EGP, up 591.0% from -31.99 million EGP in 2023.
  • Total assets at the end of 2024 were 12 billion EGP, and shareholders' equity 4.41 billion EGP.
  • Operating cash flow in 2024 was positive at 222 million EGP.

Minapharm Pharmaceuticals's Q3 2026 results are expected around 15 November — we email you the day they land

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

AI summary

Preparing a summary of the latest results…

Annual net profit last 5 years
Net profit
301million
466million
613million
−31.99million
157million
20202021202220232024

Summarised financial statements

Excel · Pro
Swipe the table to see the other years.
Item · EGP20202021202220232024
Income statement
Net profit301 million466 million613 million-31.99 million157 million
Gross profit985 million337 million1.61 billion1.41 billion2.15 billion
Total assets3.48 billion4.11 billion6.81 billion8.7 billion12 billion
Total liabilities1.89 billion2.16 billion3.77 billion5.19 billion7.59 billion
Shareholders' equity1.59 billion1.94 billion3.04 billion3.52 billion4.41 billion
Total liabilities and equity3.48 billion4.11 billion6.81 billion8.7 billion12 billion
Operating cash flow437 million206 million562 million106 million222 million
Investing cash flow-148 million-389 million-1.16 billion-1.41 billion-574 million
Financing cash flow-26.73 million156 million994 million1.51 billion1.32 billion
Net change in cash263 million-27.59 million394 million209 million964 million
Sign up free to see the full five years for every period.
Sign up free in seconds
With Google or your email, no password.

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. What does this line mean?

Results by period

One page per period: the figures against the same period a year earlier, and the official report.

Financial reports (22)

Other companies in Health Care & Pharmaceuticals

Ranked by latest annual net profit
All companies in the sector ←